MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling
10.1016/j.cell.2012.10.035
Crossref journal-article
Elsevier BV
Cell (78)
Bibliography

Huang, S., Hölzel, M., Knijnenburg, T., Schlicker, A., Roepman, P., McDermott, U., Garnett, M., Grernrum, W., Sun, C., Prahallad, A., Groenendijk, F. H., Mittempergher, L., Nijkamp, W., Neefjes, J., Salazar, R., ten Dijke, P., Uramoto, H., Tanaka, F., Beijersbergen, R. L., … Bernards, R. (2012). MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling. Cell, 151(5), 937–950.

Authors 21
  1. Sidong Huang (first)
  2. Michael Hölzel (additional)
  3. Theo Knijnenburg (additional)
  4. Andreas Schlicker (additional)
  5. Paul Roepman (additional)
  6. Ultan McDermott (additional)
  7. Mathew Garnett (additional)
  8. Wipawadee Grernrum (additional)
  9. Chong Sun (additional)
  10. Anirudh Prahallad (additional)
  11. Floris H. Groenendijk (additional)
  12. Lorenza Mittempergher (additional)
  13. Wouter Nijkamp (additional)
  14. Jacques Neefjes (additional)
  15. Ramon Salazar (additional)
  16. Peter ten Dijke (additional)
  17. Hidetaka Uramoto (additional)
  18. Fumihiro Tanaka (additional)
  19. Roderick L. Beijersbergen (additional)
  20. Lodewyk F.A. Wessels (additional)
  21. René Bernards (additional)
References 55 Referenced 382
  1. 10.1038/ng.2279 / Nat. Genet. / Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer by Barbieri (2012)
  2. 10.1038/nature02371 / Nature / A large-scale RNAi screen in human cells identifies new components of the p53 pathway by Berns (2004)
  3. 10.1016/j.ccr.2007.08.030 / Cancer Cell / A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer by Berns (2007)
  4. 10.1038/nchembio774 / Nat. Chem. Biol. / An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors by Brummelkamp (2006)
  5. 10.1056/NEJMoa1103782 / N. Engl. J. Med. / Improved survival with vemurafenib in melanoma with BRAF V600E mutation by Chapman (2011)
  6. 10.1056/NEJMoa1007478 / N. Engl. J. Med. / EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors by Choi (2010)
  7. 10.1016/j.tibs.2005.03.002 / Trends Biochem. Sci. / The mammalian Mediator complex and its role in transcriptional regulation by Conaway (2005)
  8. 10.1038/nature07179 / Nature / CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity by Firestein (2008)
  9. 10.1093/nar/gkp995 / Nucleic Acids Res. / COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer by Forbes (2010)
  10. 10.1158/0008-5472.CAN-07-2460 / Cancer Res. / Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells by Fuchs (2008)
  11. 10.1038/nature11005 / Nature / Systematic identification of genomic markers of drug sensitivity in cancer cells by Garnett (2012)
  12. 10.1126/science.1062538 / Science / Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification by Gorre (2001)
  13. 10.1016/j.cell.2010.06.004 / Cell / NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome by Hölzel (2010)
  14. 10.1016/j.ccr.2009.02.023 / Cancer Cell / ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome by Huang (2009)
  15. 10.1038/nature09627 / Nature / COT drives resistance to RAF inhibition through MAP kinase pathway reactivation by Johannessen (2010)
  16. 10.1056/NEJMoa0804385 / N. Engl. J. Med. / K-ras mutations and benefit from cetuximab in advanced colorectal cancer by Karapetis (2008)
  17. 10.1042/BJ20111923 / Biochem. J. / TGF-β sensitivity is determined by N-linked glycosylation of the type II TGF-β receptor by Kim (2012)
  18. 10.1056/NEJMoa1006448 / N. Engl. J. Med. / Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer by Kwak (2010)
  19. {'key': '10.1016/j.cell.2012.10.035_bib19', 'first-page': '4', 'article-title': 'EMT is the dominant program in human colon cancer', 'volume': '2011', 'author': 'Loboda', 'year': '2011', 'journal-title': 'BMC Medical Genomics'} / BMC Medical Genomics / EMT is the dominant program in human colon cancer by Loboda (2011)
  20. 10.1056/NEJMoa0909530 / N. Engl. J. Med. / Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR by Maemondo (2010)
  21. 10.1126/science.1208930 / Science / MED12, the mediator complex subunit, 12 gene is mutated at high frequency in uterine leiomyomas by Mäkinen (2011)
  22. 10.1126/science.1075762 / Science / The protein kinase complement of the human genome by Manning (2002)
  23. 10.1158/0008-5472.CAN-07-6186 / Cancer Res. / Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors by McDermott (2008)
  24. 10.1200/JCO.2010.30.1077 / J. Clin. Oncol. / Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer by Salazar (2011)
  25. 10.1126/scitranslmed.3002003 / Sci. Transl. Med. / Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors by Sequist (2011)
  26. 10.1016/S1535-6108(02)00096-X / Cancer Cell / Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia by Shah (2002)
  27. 10.1016/j.cell.2010.02.027 / Cell / A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations by Sharma (2010)
  28. 10.1016/j.cell.2009.11.007 / Cell / Epithelial-mesenchymal transitions in development and disease by Thiery (2009)
  29. 10.1016/j.lungcan.2011.01.008 / Lung Cancer / Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma by Uramoto (2011)
  30. 10.1200/JCO.2010.33.2312 / J. Clin. Oncol. / Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling by Wagle (2011)
  31. 10.1073/pnas.1009472107 / Proc. Natl. Acad. Sci. USA / TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer by Yao (2010)
  32. 10.1073/pnas.0709662105 / Proc. Natl. Acad. Sci. USA / The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP by Yun (2008)
  33. 10.1038/cr.2008.328 / Cell Res. / Non-Smad pathways in TGF-beta signaling by Zhang (2009)
  34. Barrett, T., Troup, D.B., Wilhite, S.E., Ledoux, P., Evangelista, C., Kim, I.F., Tomashevsky, M., Marshall, K.A., Phillippy, K.H., Sherman, P.M., et al. (2011). NCBI GEO: archive for functional genomics data sets—10 years on. Nucleic Acids Res. 39(Database issue), D,1005–D1010. (10.1093/nar/gkq1184)
  35. Bibikova, M., Talantov, D., Chudin, E., Yeakley, J.M., Chen, J., Doucet, D., Wickham, E., Atkins, D., Barker, D., Chee, M., et al. (2004). Quantitative gene expression profiling in formalin-fixed paraffin-embedded tissues using universal bead arrays. Am. J. Pathol. 165, 1799–1807. (10.1016/S0002-9440(10)63435-9)
  36. Brummelkamp, T.R., Bernards, R., and Agami, R. (2002). A system for stable expression of short interfering RNAs in mammalian cells. Science 296, 550–553. (10.1126/science.1068999)
  37. Brummelkamp, T.R., Fabius, A.W., Mullenders, J., Madiredjo, M., Velds, A., Kerkhoven, R.M., Bernards, R., and Beijersbergen, R.L. (2006). An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat. Chem. Biol. 2, 202–206. (10.1038/nchembio774)
  38. Fan, J.B., Yeakley, J.M., Bibikova, M., Chudin, E., Wickham, E., Chen, J., Doucet, D., Rigault, P., Zhang, B., Shen, R., et al. (2004). A versatile assay for high-throughput gene expression profiling on universal array matrices. Genome Res. 14, 878–885. (10.1101/gr.2167504)
  39. Forbes, S.A., Tang, G., Bindal, N., Bamford, S., Dawson, E., Cole, C., Kok, C.Y., Jia, M., Ewing, R., Menzies, A., et al. (2010). COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res. 38(Database issue), D,652–D657. (10.1093/nar/gkp995)
  40. Frolik, C.A., Wakefield, L.M., Smith, D.M., and Sporn, M.B. (1984). Characterization of a membrane receptor for transforming growth factor-beta in normal rat kidney fibroblasts. J. Biol. Chem. 259, 10995–11000. (10.1016/S0021-9258(18)90612-5)
  41. Gautier, L., Cope, L., Bolstad, B.M., and Irizarry, R.A. (2004). affy—analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20, 307–315. (10.1093/bioinformatics/btg405)
  42. Gentleman, R.C., Carey, V.J., Bates, D.M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., et al. (2004). Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5, R80. (10.1186/gb-2004-5-10-r80)
  43. Hartigan, J.A., and Hartigan, P. (1985). The dip test of unimodality. Ann. Stat. 13, 70–84. (10.1214/aos/1176346577)
  44. Hölzel, M., Huang, S., Koster, J., Ora, I., Lakeman, A., Caron, H., Nijkamp, W., Xie, J., Callens, T., Asgharzadeh, S., et al. (2010). NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 142, 218–229. (10.1016/j.cell.2010.06.004)
  45. Huang, S., Laoukili, J., Epping, M.T., Koster, J., Hölzel, M., Westerman, B.A., Nijkamp, W., Hata, A., Asgharzadeh, S., Seeger, R.C., et al. (2009). ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. Cancer Cell 15, 328–340. (10.1016/j.ccr.2009.02.023)
  46. Jorissen, R.N., Gibbs, P., Christie, M., Prakash, S., Lipton, L., Desai, J., Kerr, D., Aaltonen, L.A., Arango, D., Kruhøffer, M., et al. (2009). Metastasis-associated gene expression changes predict poor outcomes in patients with dukes stage B and C colorectal cancer. Clin. Cancer Res. 15, 7642–7651. (10.1158/1078-0432.CCR-09-1431)
  47. Kortlever, R.M., Higgins, P.J., and Bernards, R. (2006). Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat. Cell Biol. 8, 877–884. (10.1038/ncb1448)
  48. Loboda, A., Nebozhyn, M.V., James, W., Watters, J.W., Carolyne, A., Buser, C.A., Shaw, P.M., Huang, P.S., Van't Veer, L.J., Tollenaar, R.A.E.M., et al. (2011). EMT is the dominant program in human colon cancer. BMC Medical Genomics 2011, 4–9. (10.1186/1755-8794-4-9)
  49. Mittempergher, L., de Ronde, J.J., Nieuwland, M., Kerkhoven, R.M., Simon, I., Rutgers, E.J., Wessels, L.F., and Van't Veer, L.J. (2011). Gene expression profiles from formalin fixed paraffin embedded breast cancer tissue are largely comparable to fresh frozen matched tissue. PLoS ONE 6 e17163. (10.1371/journal.pone.0017163)
  50. Salazar, R., Roepman, P., Capella, G., Moreno, V., Simon, I., Dreezen, C., Lopez-Doriga, A., Santos, C., Marijnen, C., Westerga, J., et al. (2011). Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J. Clin. Oncol. 29, 17–24. (10.1200/JCO.2010.30.1077)
  51. Smith, J.J., Deane, N.G., Wu, F., Merchant, N.B., Zhang, B., Jiang, A., Lu, P., Johnson, J.C., Schmidt, C., Bailey, C.E., et al. (2010). Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology 138, 958–968. (10.1053/j.gastro.2009.11.005)
  52. Taube, J.H., Herschkowitz, J.I., Komurov, K., Zhou, A.Y., Gupta, S., Yang, J., Hartwell, K., Onder, T.T., Gupta, P.B., Evans, K.W., et al. (2010). Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc. Natl. Acad. Sci. USA 107, 15449–15454. (10.1073/pnas.1004900107)
  53. Trapnell, C., Pachter, L., and Salzberg, S.L. (2009). TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105–1111. (10.1093/bioinformatics/btp120)
  54. Wang, L., Feng, Z., Wang, X., Wang, X., and Zhang, X. (2010). DEGseq: an R package for identifying differentially expressed genes from RNA-seq data. Bioinformatics 26, 136–138. (10.1093/bioinformatics/btp612)
  55. Yamashita, H., ten Dijke, P., Huylebroeck, D., Sampath, T.K., Andries, M., Smith, J.C., Heldin, C.H., and Miyazono, K. (1995). Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects. J. Cell Biol. 130, 217–226. (10.1083/jcb.130.1.217)
Dates
Type When
Created 12 years, 9 months ago (Nov. 21, 2012, 10:17 a.m.)
Deposited 3 years, 10 months ago (Oct. 29, 2021, 9:29 p.m.)
Indexed 2 days, 23 hours ago (Sept. 3, 2025, 6 a.m.)
Issued 12 years, 10 months ago (Nov. 1, 2012)
Published 12 years, 10 months ago (Nov. 1, 2012)
Published Print 12 years, 10 months ago (Nov. 1, 2012)
Funders 0

None

@article{Huang_2012, title={MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling}, volume={151}, ISSN={0092-8674}, url={http://dx.doi.org/10.1016/j.cell.2012.10.035}, DOI={10.1016/j.cell.2012.10.035}, number={5}, journal={Cell}, publisher={Elsevier BV}, author={Huang, Sidong and Hölzel, Michael and Knijnenburg, Theo and Schlicker, Andreas and Roepman, Paul and McDermott, Ultan and Garnett, Mathew and Grernrum, Wipawadee and Sun, Chong and Prahallad, Anirudh and Groenendijk, Floris H. and Mittempergher, Lorenza and Nijkamp, Wouter and Neefjes, Jacques and Salazar, Ramon and ten Dijke, Peter and Uramoto, Hidetaka and Tanaka, Fumihiro and Beijersbergen, Roderick L. and Wessels, Lodewyk F.A. and Bernards, René}, year={2012}, month=nov, pages={937–950} }